Consistent with prior research [30–33], neutropenia, hyperuricemia, elevated LDH and cystatin-C were associated with unfavorable outcomes for advanced cancer patients in the palliative care unit regardless of the cancer origin and other clinical characteristics and biomarkers. Here, CST3 is linked to hyperuricemia.